Pegvisomant-Induced Cholestatic Hepatitis in an Acromegalic Patient with UGT1A1 (⁎) 28 Mutation

Pegvisomant (PEGv) is a growth hormone receptor antagonist approved for the treatment of acromegaly; one of its documented adverse effects is reversible elevation of hepatic enzymes. We report a 39-year-old male acromegalic patient with a pituitary macroadenoma who underwent transsphenoidal surgery....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Case Rep Endocrinol
Main Authors: Mallea-Gil, Maria Susana, Bernabeu, Ignacio, Spiraquis, Adriana, Avangina, Alejandra, Loidi, Lourdes, Ballarino, Carolina
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2016
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4763006/
https://ncbi.nlm.nih.gov/pubmed/26977326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/2087102
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados